iShares Biotechnology ETF

Frequently Asked Questions About IBB

What does IBB invest in?

The iShares Biotechnology ETF (IBB) is designed to mirror the investment performance of a specific market index. This index comprises publicly traded stocks from companies operating within the U.S. biotechnology sector.

What is the expense ratio of IBB?

iShares Biotechnology ETF (IBB) charges an expense ratio of 0.44%. This is the annual fee deducted from fund assets to cover management and operations.

How big is IBB?

iShares Biotechnology ETF (IBB) manages $10.73B in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is IBB actively managed or an index fund?

IBB's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was IBB launched?

iShares Biotechnology ETF (IBB) launched in February 2001 and is managed by IShares.

How has IBB performed?

IBB's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.